Editorial Articles | The Scientist Magazine®| Page 5

Meet This Issue's Contributors

December 5, 2005

was born in Tel Aviv and came to the United States in 1975.

Top 5 Grouches of 2005

By Richard Gallagher(rgallagher@the-scientist.com) | December 5, 2005

we discuss the issues that have had an impact on infrastructure and business in the life sciences. As ever, science marches on.

0 Comments

Vaccines are Back

By Richard Gallagher(rgallagher@the-scientist.com) | November 21, 2005

The last time I wrote about vaccines was two years ago – November 17, 2003, to be precise.1 That editorial crackled with frustration about the status of the most effective health intervention that has ever been invented:"Vaccines are unattractive targets for industry, underappreciated from the public health perspective, underfunded by basic research organizations, and treated with suspicion by the public."It's a pleasure to report that, two years later, there are the beginnings of a remark

0 Comments

The Challenges Facing Neuroscience

By Richard Gallagher(rgallagher@the-scientist.com) | November 7, 2005

Neuroscience is intellectually the broadest and most taxing field in life sciences, and technologically it is the most challenging.

1 Comment

Time for Rapid Rebuttal Technology

By Richard Gallagher(rgallagher@the-scientist.com) | October 24, 2005

I hadn't realized until recently that the United States is in the grip of a mania.

0 Comments

Why We Need Institutional Repositories

By Richard Gallagher(rgallagher@the-scientist.com) | October 10, 2005

It used to be that the record of scientific work was complete when it was all published in journals.

0 Comments

Let's Talk About This

By Richard Gallagher(rgallagher@the-scientist.com) | September 26, 2005

How do scientists communicate, with one another and with the public?

0 Comments

Combating Malevolence

By Richard Gallagher(rgallagher@the-scientist.com) | September 12, 2005

Whatever the entertainment and artistic merits of the movie "The Constant Gardener," released at the end of last month, the pharmaceutical industry could do without it.

0 Comments